Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2024 | NSCLC | Correction

Correction: RPTOR blockade suppresses brain metastases of NSCLC by interfering the ceramide metabolism via hijacking YY1 binding

Authors: Ying Lin, Yun Wu, Qiangzu Zhang, Xunwei Tu, Sufang Chen, Junfan Pan, Nengluan Xu, Ming Lin, Peiwei She, Gang Niu, Yusheng Chen, Hongru Li

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2024

Excerpt

Correction: J Exp Clin Cancer Res 43, 1 (2024) …

Lin Y, Wu Y, Zhang Q, et al. RPTOR blockade suppresses brain metastases of NSCLC by interfering the ceramide metabolism via hijacking YY1 binding. J Exp Clin Cancer Res. 2024;43:1. https://doi.org/10.1186/s13046-023-02874-z.CrossRefPubMedPubMedCentral

Title: Correction: RPTOR blockade suppresses brain metastases of NSCLC by interfering the ceramide metabolism via hijacking YY1 binding
Authors: Ying Lin
Yun Wu
Qiangzu Zhang
Xunwei Tu
Sufang Chen
Junfan Pan
Nengluan Xu
Ming Lin
Peiwei She
Gang Niu
Yusheng Chen
Hongru Li
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: NSCLC
NSCLC
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2024
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-024-02961-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2024

Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept

LncRNA AL139294.1 can be transported by extracellular vesicles to promote the oncogenic behaviour of recipient cells through activation of the Wnt and NF-κB2 pathways in non-small-cell lung cancer

Identification of genetic modifiers enhancing B7-H3-targeting CAR T cell therapy against glioblastoma through large-scale CRISPRi screening

Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response

KLF7 regulates super-enhancer-driven IGF2BP2 overexpression to promote the progression of head and neck squamous cell carcinoma

Inhibition of choline metabolism in an angioimmunoblastic T-cell lymphoma preclinical model reveals a new metabolic vulnerability as possible target for treatment

Keynote webinar | Spotlight on antibody–drug conjugates in cancer